Revenue YoY
+82.57%
Operating Income YoY
+751.92%
Net Income YoY
+314.00%
Net Margin Δ
+2499 bps
Net income bridge for Alnylam Pharmaceuticals (ALNY) — TTM through Q1 2026 vs TTM through Q1 2025
Δ Net income: $846.92M+314.00%
Profit bridge breakdown for Alnylam Pharmaceuticals (ALNY) — TTM through Q1 2026 vs TTM through Q1 2025
| Driver | Contribution | % of Δ |
|---|---|---|
| Prior Net Income | −$269.70M | — |
| Revenue | $1.94B | +228.9% |
| Cost of Revenue | −$490.59M | -57.9% |
| Operating Expenses | −$580.72M | -68.6% |
| Other Income / Expense | $74.28M | +8.8% |
| Income Tax | −$63.54M | -7.5% |
| Other Items | −$31.32M | -3.7% |
| Net Income | $577.22M | — |
- Prior Net Income−$269.70M
- Revenue$1.94B
- Cost of Revenue−$490.59M
- Operating Expenses−$580.72M
- Other Income / Expense$74.28M
- Income Tax−$63.54M
- Other Items−$31.32M
- Net Income$577.22M
Identity check: drivers reconcile to ΔNI within $0.00 ✓
Want the full P&L structure?Income Statement Waterfall
Frequently asked questions
Data & methodology
Alnylam Pharmaceuticals (ALNY) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Cash Flow
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement